α-glucosidase i

Celgosivir (6 O-butanoyl castanospermine) is an inhibitor of α-glucosidase I. In vitro assay, it inhibits bovine viral diarrhoea virus (BVDV) ( IC50: 1.27 μM ).

IHVR-17028 is a potent broad-spectrum ERα-glucosidase I (α-glucosidase I) inhibitor with IC50 of 0.24 μM and antiviral activity. IHVR-17028 inhibited BVDV, TCRV and DENV, and EC50 values were 0.4 μM, 0.26 μM and 0.3 μM, respectively. IHVR-17028 can be used to study infectious diseases.

α-Glucosidase-IN-23 is an orally active inhibitor of α-glucosidase that can decrease blood glucose levels by inhibiting α-glucosidase (IC50 = 4.48 μM).

α-Glucosidase-IN-4 is a potent α-glucosidase inhibitor exhibiting antihypertensive and hypoglycemic activity.

Celgosivir hydrochloride (MBI 3253 hydrochloride) is an α-glucosidase I inhibitor and inhibits bovine viral diarrhoea virus (BVDV) (IC50: 1.27 μM).

α-Glucosidase-IN-83 (compound I-1) is a potent inhibitor of α-glucosidase, demonstrating an IC50 of 1.49 μg/mL. This compound effectively reduces blood glucose levels in vivo.

α-Glucosidase-IN-30 (compound 8c) is a potent, orally active competitive inhibitor of α-glucosidase, with a K i of 40.0 µM and an IC50 of 49.0 µM. Non-cytotoxic to both cancerous MCF-7 and normal HDF cell lines, it is suitable for Type 2 diabetes research [1].

α-Glucosidase-IN-63 (Compound 4d) serves as an α-Glucosidase inhibitor with an IC 50 value of 0.44 μM. Additionally, it exhibits inhibitory activity against hCA II, demonstrating a K i of 7.0 nM. The compound is also effective when administered orally. [1]

α-Glucosidase-IN-72 (compound 5i), a 2,4-dichloro-N-phenylacetamide derivative, functions as an α-glucosidase inhibitor with an inhibitory concentration (IC 50) of 6 μM. Notably, it does not adhere to Lipinski's "rule of five" and is not a cancer inducer.

α-Glucosidase-IN-73 (compound 16b), an α-Glucosidase inhibitor, exhibits an IC 50 value of 0.158 μM and possesses the ability to activate PPAR γ. This compound is applicable in studies focusing on anti-diabetic and anti-inflammatory treatments.

α-Glucosidase-IN-74, a nicotinamide-thiazole derivative, functions as an α-glucosidase (α-glucosidase) inhibitor. It demonstrates antidiabetic activity by reducing blood glucose and triglyceride levels in Streptozotocin-induced diabetic animals.

α-Glucosidase-IN-75 (compound 13) is an inhibitor of α-glucosidase, exhibiting an IC50 value of 3.81 μM. It is employed in the study of cardiovascular diseases induced by high glucose levels.

α-Glucosidase-IN-76 (Compound 4r) is an inhibitor of α-glucosidase, with an IC50 of 5.44 μM. It can clear ABTS+ free radicals, with a TEAC value of 0.49. Additionally, α-Glucosidase-IN-76 inhibits the proliferation of T24 bladder cancer cells, with an IC50 of 1.74 μM.

α-Glucosidase-IN-77 (Compound H7) is a non-competitive α-glucosidase inhibitor with an IC50 of 1.25 μM. It reduces blood glucose levels, improves glucose tolerance, regulates gut microbiota, and exhibits hepatoprotective effects in a mouse model of type 2 diabetes.

α-Glucosidase-IN-82 (compound 8l) is a potent inhibitor of α-glucosidase, with an IC50 value of 13.66 μM. Its inhibitory activity is 52 times greater than that of Acarbose.

α-Glucosidase-IN-78 (Compound 12m) is a reversible competitive inhibitor of α-glucosidase (α-glucosidase) with an IC50 of 6.0 μM. Due to its blood sugar-lowering properties, α-Glucosidase-IN-78 is applicable in diabetes research.

α-Glucosidase-IN-79 (Compound 4d9) is a non-competitive α-glucosidase inhibitor with an IC50 of 2.11 μM, demonstrating greater inhibitory potency than the existing α-glucosidase inhibitors Acarbose (IC50 of 327.0 μM) and HXH8r (IC50 of 15.32 μM). It exhibits no cytotoxicity on normal human liver cells (LO2) and shows good metabolic stability in rat plasma. α-Glucosidase-IN-79 holds promise for research in type 2 diabetes.

α-Amylase/α-Glucosidase-IN-18 (Compound 9g) is an inhibitor of α-amylase and α-glucosidase, with IC50 values of 49.17 nM and 10.71 nM, respectively. It is suitable for research related to type 2 diabetes.

α-Amylase/α-Glucosidase-IN-17 (Compound 3) is an inhibitor of α-amylase and α-glucosidase, with IC50 values of 14.61 μM and 25.38 μM, respectively. It exhibits some inhibitory activity against A549 cancer cells and possesses both antitumor and antidiabetic properties.

α-Glucosidase-IN-84 (Compound 7j) is a competitive inhibitor of α-glucosidase, exhibiting an IC50 of 50 μM and a Ki of 32 μM. It shows potential for application in metabolic disease research, particularly in studies related to type 2 diabetes.

α-Glucosidase-IN-81 (Compound 5) is a potent α-glucosidase inhibitor, exhibiting an IC50 value of 5.30 μM. It holds potential for diabetes research.

α-Glucosidase-IN-80 (Compound 10n) is a potent competitive inhibitor of α-glucosidase, with an IC50 of 48.4 μM. It exhibits favorable pharmacokinetic properties and toxicity profiles, making it suitable for research in diabetes-related conditions.

α-Glucosidase-IN-87 (Compound 11c) is an orally active inhibitor of α-glucosidase with an IC50 of 119.7 μM. It exhibits hypoglycemic properties and is applicable in research on metabolic diseases such as diabetes.

α-Glucosidase-IN-85 (Compound 8D1) functions as an inhibitor of α-Glucosidase, with an IC50 of 5.43 μM. This compound is useful for research related to type 2 diabetes.